[
    [
        {
            "time": "",
            "original_text": "医药行业周报：医药子板块表现分化 关注医保谈判进程",
            "features": {
                "keywords": [
                    "医药",
                    "子板块",
                    "分化",
                    "医保谈判"
                ],
                "sentiment_score": 0.5,
                "policy_related": "true",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "医药行业周报：医药子板块表现分化 关注医保谈判进程",
                "Correlation": 6,
                "Sentiment": 5,
                "Importance": 7,
                "Impact": 6,
                "Duration": 7,
                "Entity_Density": 3,
                "Market_Scope": 9,
                "Time_Proximity": 6,
                "Headline_Structure": 6,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "original_text": "贝达药业（300558.SZ）：FENLAI TAN减持期届满 累计减持46.1万股 减持股份",
            "features": {
                "keywords": [
                    "贝达药业",
                    "FENLAI TAN",
                    "减持",
                    "46.1万股"
                ],
                "sentiment_score": -0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "贝达药业（300558.SZ）：FENLAI TAN减持期届满 累计减持46.1万股 减持股份",
                "Correlation": 10,
                "Sentiment": 4,
                "Importance": 7,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "贝达药业：FENLAI TAN减持0.11%股份，减持计划时间区间届满 拟减持股份",
            "features": {
                "keywords": [
                    "贝达药业",
                    "FENLAI TAN",
                    "减持",
                    "0.11%",
                    "届满"
                ],
                "sentiment_score": -0.6,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "贝达药业：FENLAI TAN减持0.11%股份，减持计划时间区间届满 拟减持股份",
                "Correlation": 10,
                "Sentiment": 4,
                "Importance": 6,
                "Impact": 5,
                "Duration": 5,
                "Entity_Density": 10,
                "Market_Scope": 3,
                "Time_Proximity": 8,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "国产抗肿瘤药获准临床，为境内外均未上市的创新品种",
            "features": {
                "keywords": [
                    "国产",
                    "抗肿瘤药",
                    "获准临床",
                    "创新品种"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "国产抗肿瘤药获准临床，为境内外均未上市的创新品种",
                "Correlation": 5,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 8,
                "Entity_Density": 4,
                "Market_Scope": 7,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "original_text": "贝达药业新药BPI-23314获准临床",
            "features": {
                "keywords": [
                    "贝达药业",
                    "新药",
                    "BPI-23314",
                    "获准临床"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "贝达药业新药BPI-23314获准临床",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 8,
                "Duration": 9,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 9,
                "Headline_Structure": 8,
                "Source_Recency": 9
            }
        }
    ]
]